An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer

Inclusion Criteria16

• English-speaking adult males
• Life expectancy over 10 years as assessed by treating physician
• Prior to enrollment, MRI fusion biopsy of MRI-visible lesion required (as detailed below, which includes systematic biopsy cores)
• Single focus GG2 or GG3 (additional GG1 allowed up to 6mm, noting that a single focus of disease is defined as an area seen on MRI that may be biopsied multiple times using targeted biopsies and have systematic core biopsies directly adjacent to targeted cores; all of which being considered as from the same focus)
• Histologically confirmed adenocarcinoma of prostate
• Organ-confined prostate cancer, clinical stage ≤T2bN0M0
• Visible tumor on MRI
• No clear evidence or high suspicion of extraprostatic extension or seminal vesical invasion on MRI
• Biopsy via transperineal or transrectal approach with at least 2 cores of MRI visible lesions that are PIRADS 2 or higher and 12 core systematic biopsy template (exclusion of cores from systematic template that overlap with targeted cores allowed).
• Additional performance of microultrasound guided biopsy is allowed though not required. Please note that every effort will be made to correlate microultrasound findings with MRI, in order to determine if positive results are from the same MRIvisible focus. This determination will be made by the surgeon performing the biopsy.
• Note that GGG 1 disease at sites other than ablation zone are allowed provided these are 6mm or less in size. PSA ≤15 ng/mL, or PSAD \<0.15 if PSA \>15 ng/mL
• Physician can fully visualize the prostate on transrectal ultrasound on entry biopsy
• Lesion anatomically amenable to cryotherapy treatment based on treating physician's discretion
• Willing and able to read, understand and sign the study specific informed consent document
• Willing and agreeable to comply with study protocol requirements, including focal cryotherapy ablation and all follow up visit requirements
• Patients must consent to investigative laboratory protocol (such as, but not limited to, 2021- 0560)